Results 161 to 170 of about 16,883 (239)

Real-World Outcomes of Antiretroviral Therapy in People Living With HIV in Saudi Arabia: A Three-Year Observational Cohort Study From a Tertiary Care Center. [PDF]

Cureus
Alsaeed A.
europepmc   +1 more source

Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation. [PDF]

Infect Dis (Lond)
Zheng A, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Murray EJ, Pisa PT, Goeieman B, Fox MP, Maskew M.   +10 more
europepmc   +1 more source

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis

, 2014
Dipen Patel, Sonya J. Snedecor, Wing Yu Tang, Lavanya Sudharshan, Jessica Lim, Robert L. Cuffe, Sonia Pulgar, Kim Gilchrist, Rodrigo Refoios Camejo, Jennifer Stephens, Garrett Nichols   +10 more
openalex   +2 more sources

Correction to: Correlates of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study. [PDF]

BMC Infect Dis
Moro VO, Ssenkusu JM, Kiweewa FM.
europepmc   +1 more source

Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks. [PDF]

J Antimicrob Chemother
Patel P, Milinkovic A, Grove R, Govan L, McKenna M, Wynne B, Henegar C, Martinez E, Dimondi P, Chow K, Payvandi N, Jones B.   +11 more
europepmc   +1 more source

Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom. [PDF]

J Infect Dis
Kelly C, Lester JS, Bradshaw D, Bibby DF, Mohamed H, Murphy G, Brown A, Sabin C, Geretti AM, Mbisa JL.   +9 more
europepmc   +1 more source

Prevalence of primary HIV-1 drug resistance among antiretroviral-naïve individuals in Togo in 2023: a national study. [PDF]

Front Public Health
Ouro-Medeli A, Togan RM, Serrano L, Butel C, Atoun R, Youa F, Ali-Edje K, Douffan M, Ehlan P, Tegueni K, Amenti R, Konou AA, Salou M, Ekouevi DK, Peeters M, Dagnra AC.   +15 more
europepmc   +1 more source

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

, 2018
Nikki Mulligan, Brookie M. Best, Jiajia Wang, Edmund V. Capparelli, Alice Stek, Emily Barr, Shelley Buschur, Edward P. Acosta, Elizabeth Smith, Nahida Chakhtoura, Sandra Burchett, Mark Mirochnick   +11 more
openalex   +2 more sources

Machine learning guided virtual screening of FDA approved drugs targeting GSK-3β in Alzheimer's disease. [PDF]

Sci Rep
Kumar BS, Dinesh BGH, Ganjipete S, Ramar M, Ammunje DN, Kunjiappan S, Chidambaram K, Pavadai P.   +7 more
europepmc   +1 more source

Effect of dolutegravir on ferritin, iron, and C-reactive protein among people living with HIV and co-infections

Bridget Kamurai, Raylton P. Chikwati, Donald Vhanda, T. Nyamayaro, Justen Manasa, Vinie Kouamou   +5 more
openalex   +2 more sources